ClinicalTrials.gg
Enrolling by invitationNCT07943663Updated Nov 17, 2026

Development of a Virtual Health Care Platform in Heart Failure Patients Transitioning From Hospital to Home

An interventional study of There is no other intervention, only dose changes using the device if clinically needed to treat the disease during the study in Heart Failure - NYHA II - IV, sponsored by nucleusRx Inc. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionBody Weight(the registry's first term)UnverifiedIs this wrong?Body Weight is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by nucleusRx Inc · Not applicable, Interventional, and Device feasibility

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

This Study will be performed with fifteen (15) Heart Failure (HF) patients for remote monitoring of health and medication adherence following hospital discharges. Participants will be enrolled into two groups: Group 1 (chronic) will be enrolled on Day 30 to 180 post hospital discharge and monitored for 30 days; Group 2 (Acute) will be enrolled on Day 1-3 of hospital discharge after recent HF episodes and monitored for 30 days. Each participant will receive a Pill Dispenser being developed by the study sponsor, a BP machine, a weighing scale and a smartphone loaded with the software developed by the study sponsor that can collect and summarize participant's health data for study physician's/nurse's evaluation. Both BP machine and weighing scale record participant's data automatically to send to the study team physician/nurse for evaluation of his/her health. Outpatient pharmacy will deliver 30 days (+7) of medications as prescribed by the patient's physician in the standard pharmacy vials, and the patients will procure them from their chosen pharmacy outlet. Prescription details for medications will also be sent to the participant's mobile phone.

Medications will be uploaded in the dispenser on Day 1 by the patient in presence of a visiting nurse (a member of the study team) who will review and explain medication records with the patient. Nurse will also review and set up the machine as necessary for the daily wellness parameters to be measured and entered by the patient. Data will be collected automatically for the length of the study (30 days).

A 24-hr telephone number will be available to each patient to contact study nurse for any issues related to medication dispensing and/or health.

Devices will be returned to the study investigator on Day 30 and the remaining pills in the pill dispenser will be manually counted by the study nurse in both groups for comparing against the automatically collected data.

Read the detailed description

Overview of Study Design

Heart Failure patients will be studied in two groups:

Group 1 (Chronic): Patients who were hospitalized for heart failure 30 to 180 days ago will be enrolled into the study and monitored at-home using NRX platform for 30 days Group 2 (Acute): Patients who are hospitalized after an acute heart attack will be monitored using NRX platform at home for 30 days within 72 hr of hospital discharge.

Patients in Group 1 will visit the clinic on Day 1 and Day 30 of the study for baseline and final study day data collection, respectively.

Patients in Group 2 will make clinic visits on Day 7 and Day 30 of hospital discharge for interim and final study day data collection. Group 2 baseline data will be collected on the day of hospital discharge.

Thirty-days of disease-related medications (up to 12) will be loaded in the pill dispenser in the platform based on medications supplied from patient's preferred pharmacy on the first study day for both groups. Patient will be trained to be reminded of the medication dose times through the device voice prompt and also notifications on the NRX mobile phone app. The medication will be dispensed from the dispenser following an authentication by the patient.

Patient will also be trained to collect daily at-home patient's BP, Heart Rate (HR) and weight at scheduled times, and the data will be automatically collected into the NRX system. In addition, patients will report their daily health status using a user-friendly short Q\&A prompt via the NRX smart phone app. Examples of daily health statuses are shortness of breath (SOB), peripheral swelling, headache and sleeplessness, etc. which can be configured for individual patients by the study team.

Measurements:

  1. The medication compliance data will represent every successful dose, missed dose (deliberate or not) or any error in dispense.
  2. BP, HR and weight will be measured every morning after the morning medication and between- daily and weekly changes summarized with a warning if above pre-set values occur.
  3. Wellness data will also be collected every morning when prompted by the NRX companion mobile App. This may also include patient-perceived worsening of any symptoms from previous day(s) (for example):

    1. ad-hoc reporting by patient (e.g., middle of the day or night) when patient feels unwell in either cohort
    2. patient-perceived increase or worsening of signs and symptoms from previous day(s) (e.g., ankle swelling, dry hacking cough, shortness of breath, number of pillows needed to sleep at night, dizziness, confusions, loss of appetite, etc.) data that will generate immediate actionable alert to Study Team Medical Provider including study nurse
  4. A Summary Table (pre-built) will be derived from raw data containing medication adherence, physiological measures (BP, HR and weight) and wellness data daily until the end of study period (day 30)
  5. The study nurse will count number of pills left in the dispenser at the end of the 30- day study period in both cohorts

Safety Assessments

1. AE/SAE reported by the patient based on routine or ad-hoc wellness data reporting that may substantiate a call from the monitoring nurse possibly preventing a health episode.

2 Monitoring nurse will prioritize critical patients per AE/SAE reported and displayed by NRX dashboard

Devices nucleusRx, Inc. (NRX) has developed a clinically ready minimum viable product (MVP) for testing in patients. It's complete solution, a virtual care platform, consists of a physical device - a pill dispenser and an interconnected software platform which work in an integrated manner. The platform consists of a connected pill dispenser, connected physiological monitors (BP and weight), a patient companion mobile app and the provider dashboard. The embedded software can connect with the patient's electronic health record, EHR and provider's dashboard system to collect prescription information and control the dispenser through an interactive Q\&A with patient's mobile phone.

02

Conditions studied

  • Heart Failure - NYHA II - IV

Browse trials for

Keywords

  • BP
  • HR
  • Weight
  • Daily Health
  • Medication Compliance
  • Home Monitoring
03

In context

Body Weight Unverified

658 studies on the registry are indexed under Body Weight; 77 are open to participants now.

This study's planned enrollment of 15 is below the median of 71 across 501 interventional studies indexed under Body Weight.

Browse Body Weight studies →

Lead sponsor

This is the only study on the registry with nucleusRx Inc as lead sponsor.

Compared within Body Weight, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Objectively confirmed heart failure (HF)
  2. Group 1 (chronic): Hospitalized within last one to six months Group 2 (acute): within 72 hour of hospital discharge Both groups have new onset heart failure with hospitalization for the first time
  3. The participating patient must have the physical and mental capacity to be trained to use the study medication dispensing device, BP, scale and use them correctly and operate the smart phone/tablet to answer questions related to the disease symptoms.
  4. Age range: from 18 to 89 years
  5. Patient seen by Clinical Cardiology team during hospitalization
  6. Home WIFI connectivity

Exclusion criteria

Exclusion Criteria:

  1. Patients being discharged to nursing home -
  2. Patients with terminal illness and comfort care
  3. Patients scheduled for further planned readmissions or elective procedures like coronary interventions
  4. Patients who are currently pregnant
  5. Patients with implanted devices like pacemaker, ICDs or CRT-Ds
  6. Major renal dysfunction (KD stage 3 or higher or ESRD requiring hemodialysis or peritoneal dialysis)
  7. Any other reasons related to patient safety at the discretion of the study investigator
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Group 1: Chronic

    Monitoring daily health for 30 days at home with the remote device in heart failure patients enrolled within 30-180 days of hospital discharge after a heart attack. The drug dose dispensed can be changed remotely (reduce, increase or stop) if needed and requested by the primary investigator as part of the routine medical care. Remote intervention for dose changes (increase, decrease or stop) is performed through the device connected by EHR system with the patient dashboard in doctor's office

    Device: There is no other intervention, only dose changes using the device if clinically needed to treat the disease during the study

  • Experimental
    Group 2: Acute

    Monitoring daily health for 30 days at home with the remote device in heart failure patients enrolled within 72 hours of hospital discharge following a heart attack and remote changes in drug dose can be performed by intervention through the device using the EHR communication from patient dashboard by the cardiologist if needed and requested by the primary investigator as part of routine medical care

    Device: There is no other intervention, only dose changes using the device if clinically needed to treat the disease during the study

Interventions

  • DeviceThere is no other intervention, only dose changes using the device if clinically needed to treat the disease during the study

    The embedded software of the device connects with the patient's electronic health record (EHR) and provider's dashboard system to collect prescription information and control the dispenser through an interactive Q\&A with patient's mobile phone. Patient/caregiver is trained to be reminded of the programmed medication or dose changes through the device voice prompt and/or notifications on the NRX mobile phone app. The changed medication or its dose as requested by the investigator will be dispensed from the NRX dispenser following an authentication by the patient.

06

What researchers measure

Primary outcomes

  1. Medication Compliance: If device can dispense each specific medication following the directions as prescribed by the doctor through the EHR

    Each medication will be dispensed at specific time of the day (e.g., morning, mid-day or bedtime etc.) and number of times ( e.g., once or twice daily) as prescription written and sent through EHR to the device.

    Time frame: 30 days

  2. Physiological measures of Blood Pressure (systolic and diastolic): If blood pressure is measured daily as directed by the treating physician during the study

    Patient will be instructed daily as per protocol (voice and text in the mobile phone) to use the automated blood pressure machine to measure the blood pressure. The data will be collected automatically and sent to patient dashboard through EHR for analysis on changes between days within expected level or outside the range for creating a warning in patient dashboard for clinical follow-up by the nurse/doctor in the study team.

    Time frame: 30 days

  3. Monitoring the changes in body weight in pounds (Lb) between days or within a week

    Patient will be instructed daily as per protocol (voice and text in the mobile phone) to use the automated weighing machine to measure the body weight. The data will be collected automatically and sent to patient dashboard through EHR for analysis on changes between days within expected level or outside the range for creating a warning in patient dashboard for clinical follow-up by the nurse/doctor in the study team. For example, Changes in body weight of 2 to 5 pounds within a week may provide a mild to moderate changes reflecting potential accumulation of fluids in the lung and extremities ( ankle, knee, hands, etc.)

    Time frame: over 30 says of the study

  4. Monitoring of daily wellness Data

    There will have multiple pre-designed Q\&A using the patient's mobile phone for monitoring of changes in various clinical symptoms like number of pillows needed at night to sleep (sign of heart-lung congestions) or shortness of breath (SOB) customized for the patient by the study team based on patient's background health data.

    Time frame: 30 days

Secondary outcomes

  1. Measurement of percent compliance for each medication

    The embedded software in the device will calculate daily percent compliance for each drug. For example if all drugs on a given day are dispensed on time as prescribed will be measured as 100% compliance while if one out of six daily drugs was missed on a given day, the compliance may be reported as 80% on that day identifying the missed drug dose at the specific time of the day.

    Time frame: 30 days

  2. longitudinal display of each measured parameter (medication compliance, systolic and diastolic BP, weight) over 30 days

    Each measured physiological parameter as well as each medication compliance will be calculated and plotted over days for 30 days for the study team to review the trend in health parameter changes and medication compliance data on patient data dashboard even if no parameter changed to the extent for sending a warning for clinical intervention.

    Time frame: 30 Days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 227 interventional studies with no phase under Body Weight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Nov 17, 2026
StartActual
Nov 26, 2025
Primary completionEst.
Dec 10, 2026
CompletionEst.
Jan 15, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943663
Lead sponsor
nucleusRx Inc
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 26, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ashok Rakhit, PhD
study director · nucleusRx Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion